NAVA Stock Overview
A pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Norway, Sweden, Denmark, Finland, the Netherlands, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Navamedic ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 24.80 |
| 52 Week High | NOK 40.00 |
| 52 Week Low | NOK 23.00 |
| Beta | 0.42 |
| 1 Month Change | -3.13% |
| 3 Month Change | 2.48% |
| 1 Year Change | -35.42% |
| 3 Year Change | -21.02% |
| 5 Year Change | 19.81% |
| Change since IPO | 25.25% |
Recent News & Updates
Recent updates
Is Navamedic (OB:NAVA) Using Too Much Debt?
Sep 19
Here's Why Navamedic (OB:NAVA) Can Manage Its Debt Responsibly
Feb 18Shareholders Can Be Confident That Navamedic's (OB:NAVA) Earnings Are High Quality
Nov 09Is Navamedic (OB:NAVA) A Risky Investment?
Nov 02Here's Why Navamedic (OB:NAVA) Has A Meaningful Debt Burden
Feb 22We Think Navamedic (OB:NAVA) Can Stay On Top Of Its Debt
Sep 04Is Navamedic (OB:NAVA) Using Too Much Debt?
Apr 12If You Had Bought Navamedic (OB:NAVA) Stock Three Years Ago, You Could Pocket A 166% Gain Today
Feb 18
Is Navamedic (OB:NAVA) Using Debt Sensibly?
Dec 07Shareholder Returns
| NAVA | NO Pharmaceuticals | NO Market | |
|---|---|---|---|
| 7D | 3.3% | 4.2% | -0.8% |
| 1Y | -35.4% | 0.6% | 10.0% |
Return vs Industry: NAVA underperformed the Norwegian Pharmaceuticals industry which returned 0.6% over the past year.
Return vs Market: NAVA underperformed the Norwegian Market which returned 10% over the past year.
Price Volatility
| NAVA volatility | |
|---|---|
| NAVA Average Weekly Movement | 7.2% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in NO Market | 12.1% |
| 10% least volatile stocks in NO Market | 2.6% |
Stable Share Price: NAVA has not had significant price volatility in the past 3 months compared to the Norwegian market.
Volatility Over Time: NAVA's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 45 | Kathrine E. Andreassen | navamedic.com |
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Norway, Sweden, Denmark, Finland, the Netherlands, and internationally. The company’s product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic and propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet.
Navamedic ASA Fundamentals Summary
| NAVA fundamental statistics | |
|---|---|
| Market cap | NOK 441.57m |
| Earnings (TTM) | NOK 19.62m |
| Revenue (TTM) | NOK 525.55m |
22.3x
P/E Ratio0.8x
P/S RatioIs NAVA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NAVA income statement (TTM) | |
|---|---|
| Revenue | NOK 525.55m |
| Cost of Revenue | NOK 315.24m |
| Gross Profit | NOK 210.31m |
| Other Expenses | NOK 190.69m |
| Earnings | NOK 19.62m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 12, 2025
| Earnings per share (EPS) | 1.11 |
| Gross Margin | 40.02% |
| Net Profit Margin | 3.73% |
| Debt/Equity Ratio | 46.0% |
How did NAVA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/06 19:28 |
| End of Day Share Price | 2025/02/06 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Navamedic ASA is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Espen Jørgensen | DNB Markets |
| Gediminas Ruginis | Norne Securities AS |
| Juste Subataviciute | Norne Securities AS |